在癌症中通过姐妹细胞追溯原始抵抗
Jun Dai1, Shuyu Zheng1, Matías M Falco1
1Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Nature communications
|February 7, 2024
概括
研究人员开发了ReSisTrace,以识别细微的细胞状态变化,预测癌症治疗耐药性. 这种方法揭示了先前耐药的表型,有助于发现治疗方法,在治疗前使细胞敏感,改善患者分层和治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 在癌症治疗期间,越来越多地研究了细胞状态的非遗传进化.
- 需要高分辨率的分析来检测微妙的转录变化驱动治疗耐药性.
- 血统追踪方法已经推进了对细胞状态进化的探索.
研究的目的:
- 开发一种方法,ReSisTrace,通过分析姐妹细胞的共享转录组特征来预测治疗耐药性.
- 在接受化疗或自然杀手 (NK) 细胞治疗的卵巢癌细胞中识别先前耐药的表型.
- 为了发现可以使癌细胞对治疗产生敏感性的小分子,在给药前进行治疗.
主要方法:
- 开发了ReSisTrace,一种利用姐妹细胞转录基因数据的计算工具.
- 应用ReSisTrace对用olaparib,carboplatin和NK细胞治疗的卵巢癌细胞.
- 验证了预测的抗性前形状,并确定了敏感小分子.
主要成果:
- ReSisTrace确定了具有蛋白质稳定性和mRNA监测特征的先前耐药表型.
- 发现DNA修复缺陷会影响对DNA损伤剂和NK细胞杀伤的易感性,这取决于环境.
- 确定了可以在治疗前将细胞驱动到敏感状态的小分子.
结论:
- ReSisTrace有效地解决了与治疗脆弱性相关的先前存在的转录特征.
- 这些发现促进了针对性治疗的分子患者分层.
- 这种方法有助于发现协同前敏化疗法,以克服癌症治疗耐药性.
更多相关视频
08:53Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
14.7K
11:47Time-lapse Imaging of Primary Preneoplastic Mammary Epithelial Cells Derived from Genetically Engineered Mouse Models of Breast Cancer
Published on: February 8, 2013
11.9K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:21Cancers Originate from Somatic Mutations in a Single Cell
11.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.9K
02:15Replicative Cell Senescence
3.6K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.6K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K